ArticleAlimentary pharmacology & therapeutics2018

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

B Christensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.